Tekmira Sees Resolution to Ebola Drug Clinical Hold by Year-end | GenomeWeb

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week provided an update on its investigational Ebola infection therapy TKM-Ebola, stating that it expects to provide US regulators with the information required to resume clinical testing of the drug by the fourth quarter of this year.

Meanwhile, the company is aiming to begin a Phase I study of its hepatitis B treatment TKM-HBV in 2015, and unveil its newest pipeline candidate by year-end.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.